Compare Las Vegas Sands Corp. (LVS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs DENTSPLY SIRONA Inc — how do they compare? Las Vegas Sands Corp. trades at $45.62 (market cap $29.59B), while DENTSPLY SIRONA Inc trades at $11.42 (market cap $2.27B). The key difference: Las Vegas Sands Corp. is far larger — about 13× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| LVS | XRAY | |
|---|---|---|
Market Cap | $29.59B | $2.27B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $14.68 |
52-Week Low | $44.78 | $9.64 |
Enterprise Value | $41.47B | $4.35B |
Dividend Yield | 2.63% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.75, up 0.64% over the past 24 hours, with a bearish technical signal but strong fundamentals including a P/E of 17.62 and net income margin of 12.59%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $3.02 billion in 2025 and has announced a $0.30 dividend for H2 2026, reflecting financial stability.
The outlook for LVS is cautiously optimistic, supported by analyst consensus price target of $60.75 and 59% buy ratings. Key opportunities include revenue growth and ESG achievements, while risks involve high debt levels and competitive pressures in the gaming sector. Investors should weigh solid profitability against macroeconomic and regulatory uncertainties.
DENTSPLY SIRONA (XRAY) trades at $11.32, down 2.92% today, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Net income remains negative, though margins show improvement. The stock is near its consensus price target of $11.50, with support at $11 and resistance at $12.
Outlook is cautious; while cost controls and new partnerships offer potential, persistent revenue declines and high debt levels pose significant risks. Analyst sentiment is predominantly Hold, reflecting uncertainty around the turnaround plan's success amid weak dental market demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
